These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
272 related articles for article (PubMed ID: 37859375)
1. [Clinical observation on the efficacy and safety of dupilumab in the treatment of moderate to severe atopic dermatitis]. Li CY; Chen S; Qian WL; Yang L; Zheng Q; Chen AJ; Chen J; Huang K; Fang S; Wang P; Hu L; Liu XR; Zhao XQ; Tan N; Cai T Zhonghua Yu Fang Yi Xue Za Zhi; 2023 Oct; 57(10):1590-1595. PubMed ID: 37859375 [TBL] [Abstract][Full Text] [Related]
2. [Efficacy and safety of dupilumab in the treatment of moderate to severe atopic dermatitis]. Wang JY; Zhou BJ; Cao QZ; Peng C; Chen ML; Chen X; Li J Zhonghua Yi Xue Za Zhi; 2024 Aug; 104(30):2810-2816. PubMed ID: 39085148 [No Abstract] [Full Text] [Related]
3. Efficacy and Safety of Abrocitinib in Patients with Severe and/or Difficult-to-Treat Atopic Dermatitis: A Post Hoc Analysis of the Randomized Phase 3 JADE COMPARE Trial. Simpson EL; Silverberg JI; Thyssen JP; Viguier M; Thaçi D; de Bruin-Weller M; Weidinger S; Chan G; DiBonaventura M; Biswas P; Feeney C; Koulias C; Cork MJ Am J Clin Dermatol; 2023 Jul; 24(4):609-621. PubMed ID: 37213005 [TBL] [Abstract][Full Text] [Related]
4. Validation of five patient-reported outcomes for atopic dermatitis severity in adults. Silverberg JI; Margolis DJ; Boguniewicz M; Fonacier L; Grayson MH; Ong PY; Fuxench ZC; Simpson EL Br J Dermatol; 2020 Jan; 182(1):104-111. PubMed ID: 30972740 [TBL] [Abstract][Full Text] [Related]
5. Dupilumab improves patient-reported symptoms of atopic dermatitis, symptoms of anxiety and depression, and health-related quality of life in moderate-to-severe atopic dermatitis: analysis of pooled data from the randomized trials SOLO 1 and SOLO 2. Cork MJ; Eckert L; Simpson EL; Armstrong A; Barbarot S; Puig L; Girolomoni G; de Bruin-Weller M; Wollenberg A; Kataoka Y; Remitz A; Beissert S; Mastey V; Ardeleanu M; Chen Z; Gadkari A; Chao J J Dermatolog Treat; 2020 Sep; 31(6):606-614. PubMed ID: 31179791 [No Abstract] [Full Text] [Related]
6. Retrospective Study of Dupilumab Treatment for Moderate to Severe Atopic Dermatitis in Korea: Efficacy and Safety of Dupilumab in Real-World Practice. Jang DH; Heo SJ; Jung HJ; Park MY; Seo SJ; Ahn J J Clin Med; 2020 Jun; 9(6):. PubMed ID: 32599878 [TBL] [Abstract][Full Text] [Related]
7. Dupilumab Provides Acceptable Safety and Sustained Efficacy for up to 4 Years in an Open-Label Study of Adults with Moderate-to-Severe Atopic Dermatitis. Beck LA; Deleuran M; Bissonnette R; de Bruin-Weller M; Galus R; Nakahara T; Seo SJ; Khokhar FA; Vakil J; Xiao J; Marco AR; Levit NA; O'Malley JT; Shabbir A Am J Clin Dermatol; 2022 May; 23(3):393-408. PubMed ID: 35503163 [TBL] [Abstract][Full Text] [Related]
8. Comparison of Patient-Oriented Eczema Measure and Patient-Oriented Scoring Atopic Dermatitis vs Eczema Area and Severity Index and other measures of atopic dermatitis: A validation study. Silverberg JI; Lei D; Yousaf M; Janmohamed SR; Vakharia PP; Chopra R; Chavda R; Gabriel S; Patel KR; Singam V; Kantor R; Hsu DY Ann Allergy Asthma Immunol; 2020 Jul; 125(1):78-83. PubMed ID: 32199977 [TBL] [Abstract][Full Text] [Related]
9. Dupilumab significantly improves sleep in adults with atopic dermatitis: results from the 12-week placebo-controlled period of the 24-week phase IV randomized double-blinded placebo-controlled DUPISTAD study. Merola JF; Chiou AS; During E; Costanzo A; Foley P; Alfalasi A; Gogate S; Pinter A; Dodiuk-Gad R; Simon D; Tauber M; Weller R; Pereyra-Rodriguez JJ; Ardeleanu M; Wu J; Ozturk ZE Br J Dermatol; 2023 Nov; 189(6):685-694. PubMed ID: 37562034 [TBL] [Abstract][Full Text] [Related]
10. A 52 weeks dupilumab treatment for moderate to severe atopic dermatitis in Korea: long-term efficacy and safety in real world. Jang DH; Heo SJ; Kook HD; Lee DH; Jung HJ; Park MY; Ahn J Sci Rep; 2021 Dec; 11(1):23539. PubMed ID: 34876623 [TBL] [Abstract][Full Text] [Related]
11. Early Itch Response with Abrocitinib Is Associated with Later Efficacy Outcomes in Patients with Moderate-to-Severe Atopic Dermatitis: Subgroup Analysis of the Randomized Phase III JADE COMPARE Trial. Ständer S; Kwatra SG; Silverberg JI; Simpson EL; Thyssen JP; Yosipovitch G; Zhang F; Cameron MC; Cella RR; Valdez H; DiBonaventura M; Feeney C Am J Clin Dermatol; 2023 Jan; 24(1):97-107. PubMed ID: 36512175 [TBL] [Abstract][Full Text] [Related]
12. Efficacy and Safety of Dupilumab in Chinese Patients With Atopic Dermatitis: A Real-World Study. Zhou B; Peng C; Li L; Liu R; Zhu L; Chen X; Li J Front Med (Lausanne); 2022; 9():838030. PubMed ID: 35402441 [TBL] [Abstract][Full Text] [Related]
13. Efficacy and Safety of Upadacitinib vs Dupilumab in Adults With Moderate-to-Severe Atopic Dermatitis: A Randomized Clinical Trial. Blauvelt A; Teixeira HD; Simpson EL; Costanzo A; De Bruin-Weller M; Barbarot S; Prajapati VH; Lio P; Hu X; Wu T; Liu J; Ladizinski B; Chu AD; Eyerich K JAMA Dermatol; 2021 Sep; 157(9):1047-1055. PubMed ID: 34347860 [TBL] [Abstract][Full Text] [Related]
14. Dupilumab in Adults with Moderate-to-Severe Atopic Dermatitis and Prior Use of Systemic Non-Steroidal Immunosuppressants: Analysis of Four Phase 3 Trials. Griffiths C; de Bruin-Weller M; Deleuran M; Fargnoli MC; Staumont-Sallé D; Hong CH; Sánchez-Carazo J; Foley P; Seo SJ; Msihid J; Chen Z; Cyr SL; Rossi AB Dermatol Ther (Heidelb); 2021 Aug; 11(4):1357-1372. PubMed ID: 34142350 [TBL] [Abstract][Full Text] [Related]
15. Dupilumab Treatment Provides Sustained Improvements Over 2 Years in Symptoms and Quality of Life in Adults with Atopic Dermatitis. Yosipovitch G; de Bruin-Weller M; Armstrong A; Wu JJ; Herranz P; Thaçi D; Delevry D; Bagousse GB; Zhang R; Shumel B; Rossi AB; Chao J Dermatol Ther (Heidelb); 2021 Dec; 11(6):2147-2157. PubMed ID: 34714527 [TBL] [Abstract][Full Text] [Related]
16. Severity strata for POEM, PO-SCORAD, and DLQI in US adults with atopic dermatitis. Silverberg JI; Gelfand JM; Margolis DJ; Fonacier L; Boguniewicz M; Schwartz LB; Simpson E; Grayson MH; Ong PY; Fuxench ZCC Ann Allergy Asthma Immunol; 2018 Oct; 121(4):464-468.e3. PubMed ID: 30003968 [TBL] [Abstract][Full Text] [Related]
17. Dupilumab provides important clinical benefits to patients with atopic dermatitis who do not achieve clear or almost clear skin according to the Investigator's Global Assessment: a pooled analysis of data from two phase III trials. Silverberg JI; Simpson EL; Ardeleanu M; Thaçi D; Barbarot S; Bagel J; Chen Z; Eckert L; Chao J; Korotzer A; Rizova E; Rossi AB; Lu Y; Graham NMH; Hultsch T; Pirozzi G; Akinlade B Br J Dermatol; 2019 Jul; 181(1):80-87. PubMed ID: 30791102 [TBL] [Abstract][Full Text] [Related]
18. Dupilumab Treatment in Children Aged 6-11 Years With Atopic Dermatitis: A Multicentre, Real-Life Study. Napolitano M; Fabbrocini G; Neri I; Stingeni L; Boccaletti V; Piccolo V; Amoruso GF; Malara G; De Pasquale R; Di Brizzi EV; Diluvio L; Bianchi L; Chiricozzi A; Di Guida A; Del Duca E; Moschese V; Di Lernia V; Dragoni F; Gruber M; Hansel K; Licari A; Manti S; Leonardi S; Mastorino L; Ortoncelli M; Provenzano E; Palermo A; Patella V; Peduto T; Pezzolo E; Piras V; Potestio L; Battista T; Satta R; Termine S; Palma P; Zangari P; Patruno C Paediatr Drugs; 2022 Nov; 24(6):671-678. PubMed ID: 36028611 [TBL] [Abstract][Full Text] [Related]
19. Matching-Adjusted Indirect Comparison of the Efficacy at Week 32 of Tralokinumab and Dupilumab in the Treatment of Moderate-to-Severe Atopic Dermatitis. Torres T; Sohrt Petersen A; Ivens U; Bosch Vilaro A; Stinson J; Carrascosa JM Dermatol Ther (Heidelb); 2024 Apr; 14(4):983-992. PubMed ID: 38613642 [TBL] [Abstract][Full Text] [Related]